Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Core Viewpoint - Phathom Pharmaceuticals, Inc. will host a conference call on March 6, 2025, to discuss its fourth quarter and full year 2024 financial results and provide a business update [1]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3]. - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [3]. - Vonoprazan is marketed in the U.S. as VOQUEZNA® for treating heartburn associated with Non-Erosive GERD and for the healing and maintenance of Erosive GERD [3]. - The company also offers VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for the treatment of H. pylori infection in adults [3]. Event Information - A live webcast of the conference call will be available on the Phathom website, with a recording accessible for 90 days post-meeting [2].